Monoclonal Antibodies: New Opportunities & Translational Dilemmas
- Optimising biodistribution by target selection and engineering
- Reducing off-target toxicity to improve tolerability
- Selecting the right non-clinical models to demonstrate efficacy and estimate dosimetry